Why Innovative Medicine Access Differs

Why are new medicines approved at different times?

A medicine cannot be reviewed until its manufacturer submits an application, so differences often begin before regulators assess the clinical evidence. Companies may prioritize one market, delay regional submissions or wait for additional trial data requested by a particular authority. The US Food and Drug Administration, European Medicines Agency, China National Medical Products Administration and Japan Pharmaceuticals and Medical Devices Agency also operate separate expedited-review pathways for treatments addressing serious or unmet medical needs.

Regulators generally evaluate the same core questions: whether a medicine works, whether its benefits outweigh its risks and whether manufacturing quality is reliable. However, they may differ in acceptable trial comparators, requirements for regional data, use of surrogate endpoints and expectations for post-approval studies. The International Council for Harmonisation's E17 guideline encourages multiregional clinical trials designed to support submissions across several jurisdictions, potentially reducing duplication and delay.

Does regulatory approval guarantee patient access?

Marketing authorization establishes that a therapy meets a regulator's standards for quality, safety and effectiveness; it does not ensure immediate availability in clinics. Health technology assessment bodies and insurers may separately examine comparative effectiveness, cost and budget impact before agreeing to coverage. Hospitals may also need specialist staff, diagnostic testing, infusion capacity or monitoring systems before offering complex treatments.

These additional steps are particularly important for gene therapies, biologic medicines and precision oncology drugs, which can require specialized manufacturing or biomarker testing. Access can therefore differ within the same regulatory region as reimbursement rules, treatment infrastructure and clinical eligibility criteria vary. Measuring only the first approval date may consequently underestimate the time patients wait to receive treatment.

How could delays in access to innovative treatments be reduced?

Drug developers can plan multiregional trials early, include populations relevant to each intended market and seek parallel scientific advice from regulatory authorities. Programs such as the FDA's Project Orbis demonstrate how regulators can collaborate on oncology applications while retaining independent authority over approval decisions. Shared technical standards can also make it easier to use one evidence package across multiple submissions.

Faster review must still preserve rigorous assessment of benefits, harms and manufacturing quality. Conditional or accelerated pathways may require confirmatory studies when approval relies on incomplete evidence or surrogate outcomes. Transparent reporting of submission dates, regulatory decisions, reimbursement milestones and actual treatment availability would help researchers distinguish necessary scientific review from avoidable administrative delay.